Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Brain Neoplasms 31Glioblastoma 24Gliosarcoma 22Carcinoma, Non-Small-Cell Lung 16Glioma 12Astrocytoma 11Central Nervous System Neoplasms 9Oligodendroglioma 8Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 3Salivary Gland Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Medulloblastoma 3Esthesioneuroblastoma, Olfactory 3Colonic Neoplasms 3Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Ependymoma 2Diffuse Intrinsic Pontine Glioma 2Choroid Plexus Neoplasms 2Carcinoma, Hepatocellular 2Carcinoid Tumor 2Anus Neoplasms 2Wilms Tumor 1

Interventions

Magnetic Resonance Spectroscopy 2Fluorodeoxyglucose F18 2FAPI-46 2pertuzumab 1olaparib 1lutetium Lu 177 dotatate 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Erlotinib Hydrochloride 1Drug Therapy 1Biological Therapy 1(18F)GTP1 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Gland Neoplasms × Erlotinib Hydrochloride × CNS × Clear all
NCT00947167 2017-03-03

A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Terminated
4 enrolled 5 charts
CNSEndocrineNET

Adrenal Gland Neoplasms, Carcinoid Tumor, Multiple Endocrine Neoplasia, Neuroblastoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡